Back
Compare AU
Compare JRHG vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Jpmorgan Global Research En In Eqty (H) Active ETF (JRHG) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
JRHG | DRUG | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 67 |
Median incremental investment | $0 | $738.73 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,951.68 |
Average age group | N/A | > 35 |
Key Summary
JRHG | DRUG | |
|---|---|---|
Strategy | JRHG.AX was created on 2023-11-16 by JPMorgan. The fund's investment portfolio concentrates primarily on total market equity. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | NVIDIA Corp (5.58 %) Microsoft Corp (4.82 %) JPM USD Liquidity LVNAV X (acc.) (4.77 %) | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Information Technology (55.39 %) Consumer Discretionary (15.31 %) Communication Services (12.99 %) | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 0.3 % | 0.57 % |
Key Summary
JRHG | DRUG | |
|---|---|---|
Issuer | JPMorgan | BetaShares |
Tracking index | MSCI World ex Australia - AUD - Benchmark TR Net Hedged | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.3 % | 0.57 % |
Price | $70.06 | $8.49 |
Size | $40.056 million | $168.713 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 0.98 % | 1.97 % |
Market | ASX | ASX |
First listed date | 15/11/2023 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
JRHG | DRUG | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 67 |
Median incremental investment | $0 | $738.73 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,951.68 |
Average age group | N/A | > 35 |
Pros and Cons
JRHG | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
JRHG | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |